Abstract

In the current work, we present the methodology for development of an Item Response Theory model within a non-linear mixed effects framework to characterize the longitudinal changes of the Movement Disorder Society (sponsored revision) of Unified Parkinson’s Disease Rating Scale (MDS–UPDRS) endpoint in Parkinson’s disease (PD). The data were obtained from Parkinson’s Progression Markers Initiative database and included 163,070 observations up to 48 months from 430 subjects belonging to De Novo PD cohort. The probability of obtaining a score, reported for each of the items in the questionnaire, was modeled as a function of the subject’s disability. Initially, a single latent variable model was explored to characterize the disease progression over time. However, based on the understanding of the questionnaire set-up and the results of a residuals-based diagnostic tool, a three latent variable model with a mixture implementation was able to adequately describe longitudinal changes not only at the total score level but also at each individual item level. The linear progression rates obtained for the patient-reported items and the non-sided items were similar, each of which roughly take about 50 months for a typical subject to progress linearly from the baseline by one standard deviation. However for the sided items, it was found that the better side deteriorates quicker than the disabled side. This study presents a framework for analyzing MDS–UPDRS data, which can be adapted to more traditional UPDRS data collected in PD clinical trials and result in more efficient designs and analyses of such studies.

Highlights

  • Parkinson’s disease (PD) is a chronic neurodegenerative disorder affecting the central nervous system

  • The observations used in this work consisted of individual item level Movement Disorder Society (MDS)–users.Parkinson’s Disease Rating Scale (UPDRS) records up to 48 months from 423 subjects belonging to the De Novo PD cohort

  • This pattern of observed responses for the items in MDS–UPDRS scale in the current dataset is plausible because the subjects belong to DeNoPD cohort, who had been diagnosed with PD for 2 years or less at screening

Read more

Summary

Introduction

Parkinson’s disease (PD) is a chronic neurodegenerative disorder affecting the central nervous system. Availability of physiological biomarkers or neuroimaging markers that can give indications about the disease status is one of essential prerequisites for studying disease progression. Lack of such definitive markers in PD [1] has been a major challenge in the development of newer therapies. Among a number of rating scales used for the assessment in PD, the Unified. Parkinson’s Disease Rating Scale (UPDRS), originally developed three decades ago, is still the mainstay. The composite score of the different components of this rating scale reflects the severity of the disease, i.e., higher score is indicative of a more severe disease

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.